ストックスクリーナーアプリを入手
14.33
0.62%
-0.09
プレマーケット:
14.34
0.010
+0.07%
Janux Therapeutics Inc (JANX) 最新ニュース
Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value - Seeking Alpha
EX-99.1 - SEC.gov
Janux Therapeutics halts early stage cancer program in 'prudent' move - MSN
JANX stock edges up after hours after discontinuing cancer program in favor of remaining pipeline - MSN
How Janux Therapeutics Inc. (JANX) Affects Rotational Strategy Timing - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX), Stryker (SYK) and CareDx (CDNA) - The Globe and Mail
Multiple Insiders Sold Janux Therapeutics Shares Presenting Weak Signs For Investors - simplywall.st
Janux secures $35 million milestone payment from Bristol Myers Squibb - MSN
Point72 affiliates hold 3.07M Janux shares (JANX) — 5.0% stake - Stock Titan
Janux Therapeutics | SCHEDULE 13G: Others - Moomoo
Point72 (NYSE: JANX) entities report 3.07M shares, 5.0% ownership - Stock Titan
Guggenheim Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $68 - Moomoo
A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $24 to $68 - Moomoo
Janux ends development of tumor activated T cell engager asset - MSN
Janux Therapeutics, Inc. Files 8-K Report with SEC: Company Information and Key Disclosures (April 28, 2026) - Minichart
Janux Therapeutics Adjusts Board Class Structure for Director - TipRanks
JonesTrading Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $28 - Moomoo
Janux Therapeutics (NASDAQ: JANX) moves Dobmeier to Class II seat - Stock Titan
Janux Therapeutics | ARS: Annual Report to Security Holders - Moomoo
[ARS] Janux Therapeutics, Inc. SEC Filing - Stock Titan
Janux Therapeutics (JANX) sets 2026 virtual meeting, board elections and pay vote - Stock Titan
JonesTrading Has Lowered Expectations for Janux Therapeutics (NASDAQ:JANX) Stock Price - MarketBeat
BofA cuts Janux Therapeutics stock price target on pipeline changes By Investing.com - Investing.com Canada
Janux Therapeutics Halts Early Stage Cancer Program In 'Prudent' Move - Benzinga
Stifel Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $38 - Moomoo
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development - BioSpace
Janux Therapeutics (JANX) price target decreased by 11.93% to 54.57 - MSN
Barclays downgrades Janux Therapeutics (JANX) - MSN
JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline - Stocktwits
Janux to Halt Development of Cancer Drug Candidate JANX008 - marketscreener.com
Janux discontinues EGFR-targeted cancer therapy development By Investing.com - Investing.com Canada
Here are the most and least likely M&A targets in biotech, according to Truist - MSN
Janux Therapeutics Announces Collaboration and Exclusive Worldwid - The National Law Review
Janux Therapeutics Inc. (JANX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Janux Therapeutics Inc (JANX) News, Articles, Events & Latest Updates - Stocktwits
H.C. Wainwright Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $45 - Moomoo
H.C. Wainwright reiterates Janux Therapeutics stock rating at buy By Investing.com - Investing.com Canada
(JANX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
JANX News | JANUX THERAPEUTICS INC (NASDAQ:JANX) - ChartMill
Barclays Downgrades Janux Therapeutics(JANX.US) to Sell Rating, Cuts Target Price to $14 - Moomoo
Barclays Downgrades Janux Therapeutics to Underweight From Overweight, Adjusts Price Target to $14 From $29 - marketscreener.com
Barclays cuts Janux Therapeutics stock rating on near-term concerns By Investing.com - Investing.com Canada
HC Wainwright & Co. Reiterates Janux Therapeutics (JANX) Buy Recommendation - MSN
Janux is a new Buy at Truist ahead of catalyst rich H2 - MSN
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):